Torsemide has 80–100% consistent bioavailability vs furosemide's unpredictable 10–100%. This 2026 guide covers the landmark 10-RCT meta-analysis (4,011 patients), the unique anti-fibrotic cardiac benefit furosemide lacks, a 3-loop-diuretic comparison table, all 4 FDA-approved indications with dosages, the potassium monitoring requirement, and why torsemide outperforms furosemide in reliability.